In situ assembly of enzyme inhibitors using extended tethering

Nature Biotechnology

Volumn 21, Issue 3, 2003, Pages 308-314

  Erlanson, Daniel A ^a   Lam, Joni W ^a   Wiesmann, Christian ^a   Luong, Tinh N ^a   Simmons, Robert L ^a   DeLano, Warren L ^a   Choong, Ingrid C ^a   Burdett, Matthew T ^a   Flanagan, W Michael ^a   Lee, Dennis ^a   Gordon, Eric M ^a   O'Brien, Tom ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYMES; MASS SPECTROMETRY; MOLECULES;

ENZYME INHIBITORS;

BIOTECHNOLOGY;

CASPASE 3; CYSTEINE; ENZYME INHIBITOR; LIGAND;

APOPTOSIS; ARTICLE; BIOTECHNOLOGY; COMBINATORIAL CHEMISTRY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SCREENING;

APOPTOSIS; CASPASE 3; CASPASES; COMBINATORIAL CHEMISTRY TECHNIQUES; ENZYME INHIBITORS; HUMANS; JURKAT CELLS; MASS SPECTROMETRY; MODELS, MOLECULAR; PEPTIDE LIBRARY;

EID: 0037337035     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt786     Document Type: Article

References (39)

1. McGovern, S.L., Caselli, E., Grigorieff, N. & Shoichet, B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712-1722 (2002).
2. Huc, I. & Lehn, J.M. Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc. Natl. Acad. Sci. USA 94, 2106-2110 (1997).
3. Lehn, J.M. & Eliseev, A. Dynamic combinatorial chemistry. Science 291, 2331-2332 (2001).
4. Nicolaou, K.C. et al. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. Chem. Eur. J. 7, 3824-3843 (2001).
5. Ramstrom, O. & Lehn, J.M. Drug discovery by dynamic combinatorial libraries. Nat. Rev. Drug Disc. 1, 26-32 (2002).
6. Lewis, W.G. et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Edn. Engl. 41, 1053-1057 (2002).
7. Rowan, S.J., Cantrill, S.J., Cousins, G.R.L., Sanders, J.K.M. & Stoddart, J.F. Dynamic covalent chemistry. Angew. Chem. Int. Edn. Engl. 41, 898-952 (2002).
8. Erlanson, D. et al. Site-directed ligand discovery. Proc. Natl. Acad. Sci. USA 97, 9367-9372 (2000).
9. Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
10. Thornberry, N.A. et al. A combinatorial approach defines specificities of members of the caspase family and Granzyme B. J. Biol. Chem. 272, 17907-17911 (1997).
11. Rano, T.A. et al. A combinatorial approach for determining protease specificities: application to interleukin-1β converting enzyme. Chem. Biol. 4, 149-155 (1997).
12. Kaufmann, S.H. & Hengartner, M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11, 526-534 (2001).
13. Utz, P. & Anderson, P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ, 7, 589-602 (2000).
14. Hengartner, M.O. The biochemistry of apoptosis. Nature 407, 770-776 (2000).
15. Gervais, F. et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 97, 395-406 (1999).
16. Hotchkiss, R.S. et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1, 496-501 (2000).
17. McBride, C., McPhail, L. & Steeves, J. Emerging therapeutic targets in caspasedependent disease. Emerg. Therapeutic Targets 3, 391-411 (1999).
18. Yue, T.-L., Ohlstein, E. & Ruffolo, R. Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr. Opin. Chem. Biol. 3, 474-480 (1999).
19. Nicholson, D. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).
20. Lee, D. et al. Potent and selective nonpeptide inhibitors of caspases-3 and -7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem. 275, 16007-16014 (2000).
21. Han, B. et al. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxia-ischemic brain injury. J. Biol. Chem. 277, 30128-30136 (2002).
22. Dolle, R.E. et al. P1 aspartate-based peptide α-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of interleukin-1β converting enzyme. J. Med. Chem. 37, 563-564 (1994).
23. Arkin, M. et al. Binding of small molecules to an adaptive protein:protein interface. Proc. Natl. Acad. Sci. USA, in press (2003).
24. Mittl, P.R.E. et al. Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-asp-val-ala-asp fluoromethyl ketone. J. Biol. Chem. 272, 6539-6547 (1997).
25. Margolin, N. et al. Substrate and inhibitor specificity of interleukin-1β-converting enzyme and related caspases. J. Biol. Chem. 272, 7223-7228 (1997).
26. Garcia-Calvo, M. et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273, 32608-32613 (1998).
27. Slee, E.A., Adrain, C. & Martin, S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 276, 7320-7326 (2001).
28. Fry, D.W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022-12027 (1998).
29. Tsou, H.R. et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44, 2719-2734 (2001).
30. Myers, J.K. & Widlanski, T.S. Mechanism-based inactivation of prostatic acid phosphatase. Science 262, 1451-1453 (1993).
31. Taylor, W.R. Zhang, Z.Y. & Widlanski, T.S. Quiescent affinity inactivators of protein tyrosine phosphatases. Bioorg. Med. Chem. 4, 1515-1520 (1996).
32. Ham, S.W., Park, J., Lee, S.J. & Yoo, J.S. Selective inactivation of protein tyrosine phosphatase PTP1B by sulfone analogue of naphthoquinone. Bioorg. Med. Chem. Lett. 9, 185-186 (1999).
33. Arabaci, G., Xiao-Chuan, G., Beebe, K.D., Coggeshall, K.M. & Pei, D. αHaloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J. Am. Chem. Soc. 121, 5085-5086 (1999).
34. Carter, P.H. et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. USA 98, 11879-11884, (2001).
35. Choong, I.C. et al. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based design. J. Med. Chem. 45, 5005-5022 (2002).
36. Thornberry, N.A. et al. Inactivation of interleukin-1β converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33, 3934-3940 (1994).
37. Pflugrath, J.W. The finer things in X-ray diffraction data collection. Acta Crystallogr. D55, 1718-1725 (1999).
38. Navaza, J. AMORE - an automated package for molecular replacement. Acta Crystallogr. A 50, 157-163 (1994).
39. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).